微信扫一扫
实时资讯全掌握
The private equity firm Purcell & Hyams (P&H) is considering a $17 million investment in Eizak Biotech. Eizak’s owners firmly believe that with P&H’s investment they could develop their “wonder” drug and sell the firm in six years for $120 million. Given the project’s risk, P&H believes a discount rate of 30% is reasonable.
The pre-money valuation (PRE) and P&H’s fractional ownership, respectively, are closest to (in millions):
A.
B.
C.
|